Outcome after unrelated donor leukocyte infusions
| Outcome . | CML (n = 25) . | AML (n = 23) . | ALL (n = 7) . | Other (n = 3) . | Total (n = 58) . |
|---|---|---|---|---|---|
| Response to UDLI (no. at risk)* | 24 | 19 | 4 | 3 | 50 |
| CR | 11 (46%) | 8 (42%) | 2 (50%) | 0 (0) | 21 (42%) |
| PR/NR | 13 (54%) | 10 (53%) | 1 (14%) | 2 (67%) | 26 (52%) |
| F/U < 28 days | 1 (4%) | 1 (25%) | 1 (33%) | 3 (6%) | |
| Not evaluable, CR pre-UDLI | 1 (4%) | 4 (17%) | 3 (43%) | 8 (14%) | |
| Alive, in CR† | 11 | 4 | 2 | 0 | 17 |
| Acute GVHD‡ (no. at risk) | 25 | 23 | 6 | 2 | 56 |
| 0 | 17 | 13 | 2 | 2 | 34 |
| I | 1 | 1 | 0 | 0 | 2 |
| II | 2 | 1 | 2 | 0 | 5 |
| III | 2 | 4 | 1 | 0 | 7 |
| IV | 3 | 3 | 1 | 0 | 7 |
| Not evaluable | 1 | 1 | |||
| Chronic GVHD2-153 (no. at risk) | 16 | 10 | 5 | 1 | 32 |
| None | 10 | 4 | 3 | 0 | 17 |
| Limited | 1 | 2 | 0 | 0 | 3 |
| Extensive | 3 | 4 | 2 | 1 | 10 |
| Unknown | 2 | 2 | |||
| Aplasia from UDLI (no. at risk)2-155 | 19 | 12 | 2 | 1 | 34 |
| Yes | 3 | 1 | 0 | 0 | 4 |
| No | 16 | 11 | 2 | 1 | 30 |
| Median follow-up after UDLI, weeks (range) | 38 (5-180) | 10 (4-102) | 26 (1-158) | 5 (2-24) | 22 (1-180) |
| Median survival after UDLI, weeks | 42 | 11 | 35 | 3 | 34 |
| Outcome . | CML (n = 25) . | AML (n = 23) . | ALL (n = 7) . | Other (n = 3) . | Total (n = 58) . |
|---|---|---|---|---|---|
| Response to UDLI (no. at risk)* | 24 | 19 | 4 | 3 | 50 |
| CR | 11 (46%) | 8 (42%) | 2 (50%) | 0 (0) | 21 (42%) |
| PR/NR | 13 (54%) | 10 (53%) | 1 (14%) | 2 (67%) | 26 (52%) |
| F/U < 28 days | 1 (4%) | 1 (25%) | 1 (33%) | 3 (6%) | |
| Not evaluable, CR pre-UDLI | 1 (4%) | 4 (17%) | 3 (43%) | 8 (14%) | |
| Alive, in CR† | 11 | 4 | 2 | 0 | 17 |
| Acute GVHD‡ (no. at risk) | 25 | 23 | 6 | 2 | 56 |
| 0 | 17 | 13 | 2 | 2 | 34 |
| I | 1 | 1 | 0 | 0 | 2 |
| II | 2 | 1 | 2 | 0 | 5 |
| III | 2 | 4 | 1 | 0 | 7 |
| IV | 3 | 3 | 1 | 0 | 7 |
| Not evaluable | 1 | 1 | |||
| Chronic GVHD2-153 (no. at risk) | 16 | 10 | 5 | 1 | 32 |
| None | 10 | 4 | 3 | 0 | 17 |
| Limited | 1 | 2 | 0 | 0 | 3 |
| Extensive | 3 | 4 | 2 | 1 | 10 |
| Unknown | 2 | 2 | |||
| Aplasia from UDLI (no. at risk)2-155 | 19 | 12 | 2 | 1 | 34 |
| Yes | 3 | 1 | 0 | 0 | 4 |
| No | 16 | 11 | 2 | 1 | 30 |
| Median follow-up after UDLI, weeks (range) | 38 (5-180) | 10 (4-102) | 26 (1-158) | 5 (2-24) | 22 (1-180) |
| Median survival after UDLI, weeks | 42 | 11 | 35 | 3 | 34 |
Patients in CR at time of UDLI are excluded from response analysis. Patients who did not survive 28 days for adequate follow-up are shown and are considered nonresponders for this analysis. Patients who received pre-DLI chemotherapy and were not in CR before UDLI (for instance, UDLI given at the time of chemotherapy-induced nadir) are included in this table as “evaluable” for response. For more details on patients who received pre-DLI chemotherapy, see text.
Includes all recipients of UDLI.
Follow-up 28 days or more from UDLI.
Follow-up more than 100 days from UDLI.
Aplasia from UDLI was not evaluable if the patient died before adequate follow-up (more than 28 days) or if pre-DLI chemotherapy was administered.